Normally you would think so. However, I think these funds eliminate the risk/concern of having to fund the trials. Thus, I actually see this as very positive news and the market had almost 2 hours to react to it as well. Granted, it decreases the return investors will make from the company, but that was to be expected with a pre-revenue biotech.
Market Data 
Markets 
